CE InformationDownload MaterialsCourse Progress
  • Access Webinar
  • Evaluation
  • Certificate
Evaluation

Optimizing Outcomes in IBD: The Role of Therapeutic Drug Monitoring and Precision Medicine

Evaluation

HMP Education would appreciate your feedback on the quality and impact of this activity.

Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little).

To what extent are you able to better achieve each of the following learning objectives?

Evaluate the prevalence and mechanisms of nonresponse/loss of response associated with biologic therapy
Assess the latest evidence associated with reactive and proactive TDM with regard to utility, appropriateness of initiation, and treatment adjustments based on trough levels
Implement optimal strategies and guideline recommendations for TDM, where appropriate, in the management of IBD

Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor).

Adam S. Cheifetz, MD
Raymond K Cross, MD, MS, AGAF, FACG
Marla Dubinsky, MD

Please rate the following components relating to this activity:

Content
Relevance to your practice 
Educational format 
Audience-participation portions (eg., Q&A, polling, pre/post-testing) 
Resources and/or other materials supporting the activity
Overall

Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices.
How many patients do you encounter with IBD on a weekly basis?

Do you feel like there were any new data presented?

Did you learn anything new?

Did you gain confidence on the new information?

Did this program include opportunities to learn as a part of a healthcare team?
Approximately _____ of patients discontinue anti-TNF therapy for primary non-response.
The method of __________ offers objective data to expedite therapy adjustments for individual IBD patients and has demonstrated efficacy in maintaining clinical remission.
Which of the following is a 2021 expert-recommended use of TDM?
How confident are you now in your ability to implement novel tools for TDM in your clinical practice?

Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific.
What challenges or barriers outside of your control may prevent you from changing your practice?
255 characters max

The information presented in this activity did not serve to advance a proprietary interest of any commercial entity.
Based on my participation in this activity, I anticipate I will more often (select all that apply):